Evotec bags chemical proteomics specialist Kinaxo


Hamburg-based Evotec AG is to expand its drug discovery capacity with a EUR12m acquisition. Yesterday, the company announced the purchase of private chemical proteomics specialist Kinaxo Biotechnologies GmbH. The transaction, which will cost Evotec EUR3m in cash, and EUR2.6m plus performance-based milestones up to EUR4m in cash as well EUR4m of integration costs, is expected to close in April. „Kinaxo has built a unique technology platform that allows comprehensive analysis of cancer signal transduction processes and their response to drug treatment said Kinaxo’s co-founder and world-reknown cancer researcher Prof. Dr Axel Ullrich. „The integration of the leading drug discovery capability will implement Evotec as a driver towards personalised medicine in the future." Kinaxo offers state-of-the-art quantitative techniques to analyse drug effects on a cell’s phosphoproteome or kinome to pharmaceutical companies and eases preclinical assessment of adrug candidate's efficacy, mode-of-action, target population and off-target effects. The company, which relies on three platform technologies, currently is running partnerships with BMS, AstraZeneca, Roche, Jansen Pharmaceutical, Takeda, BayerVital, or Boehringer Ingelheim. Kinaxo’s Cellular Target Profiling® platfom uncovers the protein binding partners of compounds with unknown mode-of-action with help of label-free quantitative mass spectrometry techniques developed at Martinsried-based Max-Planck-Institute of Biochemistry such as SILAC or iTraq. Its KinAffinity® platform gives Evotec the capability to screen for a drug candidate’s interactions with all 340 cellular protein kinases, the most important class of targeted cancer drugs.The third proteomics application termed PhosphoScout® provides insight in a drug’s mode-of-action in vivo by identifying its interference with cellular signal pathways. On the other hand it provides biomarkers for stratification of drug responders. "Through the acquisition of Kinaxo, Evotec gains access to a highly innovative technology base in drug discovery," said Dr Werner Lanthaler, Chief Executive Officer of Evotec AG."

Germany, FranceGermany


Martinsried/Paris - Sanofi has done some Christmas shopping in Munich and has licensed Scil Technology’s programme for the regenerative treatment of osteoarthritis and cartilage disorders. Under the agreement, Scil could reap up...



Monheim - It's nearly Christmas, and Bayer Crop Science gives out some presents. As the company announced, a $750 million settlement with U.S. rice farmers is now binding and can move forward. In summer the German firm had agreed...



Bonn – Germany’s federal government is prolonging one of its most successful measures to date for stimulating the establishment of high-tech companies – the High-Tech-Gründerfonds (HTGF). The HTGF was launched in 2005 with €272m...



Leverkusen – One short statement from the European Medicines Agency (EMA) means one giant step for German biotech company Biofrontera. The agency issued a favourable opinion on the firm’s marketing approval application for its...



While the European sovereign debt crisis keeps capital markets in a choke-hold, with potential negative effects on the financing situation in many industries – including biotech – there was encouraging news for drug-developing...



Heidelberg – There is still life in the European life science finance. EMBL Ventures has closed a €40m fund. The early stage investor and the venture capital arm of the European Molecular Biology Laboratory(EMBL) announced the...



Düsseldorf – BIO-Europe 2011 in Düsseldorf has again broken all previous records in terms of participants and company numbers. More than 3,000 representatives from 1,800 companies registered for Europe‘s largest partnering event....



Brussels/San Francisco – As the biggest biotech partnering event on the continent, BioEurope, draws to a close, the venture capital community sent ambivalent messages for life sciences. Dow Jones VentureSource, an analyst,...

Displaying results 11 to 20 out of 454

< Previous 11-20 Next >

© 2007-2015 BIOCOM


All videos

Product of the week



LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...


All Events



BioVaria 2015

Job Advert

Sales Manager

celares GmbH is a Berlin based drug delivery company focused on chemical modifications of biological drugs. We offer customized development services for international pharma and biopharma companies and have manufacturing capabilities for key starting materials used for the preparation of pharmaceutical drugs. For the intensification of our own sales activities we are looking for a sales manager. more...

Stock list

All quotes


  • CO.DON2.97 EUR2.41%
  • MOLOGEN5.06 EUR0.80%
  • CYTOS1.28 CHF0.79%


  • MEDIGENE12.90 EUR-11.03%
  • 4SC1.18 EUR-5.60%
  • PAION2.37 EUR-5.58%


  • MEDIGENE12.90 EUR93.4%
  • 4SC1.18 EUR66.2%
  • FORMYCON31.00 EUR37.7%


  • CYTOS1.28 CHF-14.7%
  • MORPHOSYS60.74 EUR-12.8%
  • BB BIOTECH281.20 EUR-11.3%


  • SANTHERA99.75 CHF2709.9%
  • CYTOS1.28 CHF652.9%
  • FORMYCON31.00 EUR336.6%


  • MOLOGEN5.06 EUR-53.1%
  • PAION2.37 EUR-22.3%
  • BIOFRONTERA2.57 EUR-21.2%

No liability assumed, Date: 17.04.2015

Current issue

All issues